IRIS
ARBITRIO, Mariamena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 697
EU - Europa 604
AS - Asia 431
SA - Sud America 46
AF - Africa 21
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 1.810
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 664
IT - Italia 323
SG - Singapore 220
DE - Germania 69
GB - Regno Unito 67
IN - India 46
BR - Brasile 35
FI - Finlandia 35
CN - Cina 27
HK - Hong Kong 23
SE - Svezia 23
CA - Canada 22
JO - Giordania 21
PK - Pakistan 20
NL - Olanda 18
ID - Indonesia 17
ES - Italia 10
FR - Francia 10
RU - Federazione Russa 9
SA - Arabia Saudita 9
ZA - Sudafrica 8
CZ - Repubblica Ceca 7
LT - Lituania 7
PT - Portogallo 7
AE - Emirati Arabi Uniti 6
MX - Messico 6
AU - Australia 5
EG - Egitto 5
IE - Irlanda 5
IQ - Iraq 5
IR - Iran 5
BD - Bangladesh 4
CY - Cipro 4
EU - Europa 4
TR - Turchia 4
BG - Bulgaria 3
EC - Ecuador 3
ET - Etiopia 3
JP - Giappone 3
KR - Corea 3
LB - Libano 3
NG - Nigeria 3
PE - Perù 3
PH - Filippine 3
RO - Romania 3
UA - Ucraina 3
CO - Colombia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
LK - Sri Lanka 2
MA - Marocco 2
MY - Malesia 2
PS - Palestinian Territory 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AT - Austria 1
CH - Svizzera 1
CL - Cile 1
NZ - Nuova Zelanda 1
OM - Oman 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VN - Vietnam 1
Totale 1.810
Salva come PNG Salva come JPEG
Città #
Singapore 160
Chandler 124
Chicago 48
Munich 46
Santa Clara 46
Ashburn 40
London 38
Milan 26
Lawrence 24
Princeton 24
Turku 24
Catanzaro 22
Naples 17
Amman 13
Carbonia 12
Hong Kong 12
Helsinki 11
Boardman 10
Los Angeles 10
Ottawa 10
Parma 10
San Nicola Manfredi 10
Spezzano della Sila 10
The Dalles 10
Wilmington 10
Rome 9
Delhi 8
Irbid 8
New York 8
Kaunas 7
Madrid 7
San Francisco 7
Santo Stefano di Rogliano 7
Cosenza 6
Ercolano 6
São Paulo 6
Afragola 5
Brooklyn 5
Cardiff 5
Des Moines 5
Frankfurt am Main 5
Lucknow 5
Olomouc 5
Redmond 5
Riyadh 5
Sacramento 5
Stockholm 5
Brescia 4
Chennai 4
Jeddah 4
Lahore 4
Nicosia 4
Pune 4
Redwood City 4
Richmond 4
Seattle 4
West Jordan 4
Acquaviva delle Fonti 3
Addis Ababa 3
Ajman 3
Atlanta 3
Banyumas 3
Berlin 3
Bologna 3
Bristol 3
Castrovillari 3
Catania 3
Dubai 3
Faisalabad 3
Grottaglie 3
Hyderabad 3
Islamabad 3
Lima 3
Melito di Porto Salvo 3
Mileto 3
Noida 3
Nuremberg 3
Oxford 3
Palermo 3
Paola 3
Quţūr 3
San Antonio 3
Santo Tirso 3
Seoul 3
Shanghai 3
Sofia 3
Washington 3
Waterford 3
Agrigento 2
Amsterdam 2
Assago 2
Asyut 2
Augusta 2
Bekasi 2
Benevento 2
Bogotá 2
Buffalo 2
Campobello di Licata 2
Cape Town 2
Charlotte 2
Totale 1.058
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 352
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 84
miR-22 suppresses DNA ligase III addiction in multiple myeloma 84
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 78
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 68
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 53
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 51
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 48
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 46
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 45
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 44
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 43
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 43
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 40
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 40
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 39
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 39
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 39
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 38
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 37
Mmrf-commpass data integration and analysis for identifying prognostic markers 37
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 35
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 34
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 33
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 32
Integration of DNA Microarray with Clinical and Genomic Data 32
null 31
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 30
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 30
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 29
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 28
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 27
Ethical Perspectives on Pharmacogenomic Profiling 23
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 23
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 22
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity 21
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 21
Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS 20
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 19
Autophagy and neuroprotection in astrocytes exposed to 6-hydroxydopamine is negatively regulated by NQO2: relevance to Parkinson’s disease 19
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 17
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 14
Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future 9
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis 7
Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis 6
Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity 6
null 2
Totale 1.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202163 6 1 4 7 6 6 6 7 8 11 1 0
2021/2022128 2 0 0 22 5 2 10 22 30 17 13 5
2022/2023376 54 28 29 10 42 30 5 28 40 42 47 21
2023/2024469 87 34 42 37 41 70 27 38 10 17 32 34
2024/2025843 74 20 28 42 51 109 51 53 51 22 149 193
2025/20267 7 0 0 0 0 0 0 0 0 0 0 0
Totale 1.918